RSS

myeloma

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Clinical-stage biopharmaceutical company, Autolus, has announced the publication of pre-clinical data of a novel, dual-targeted, proliferating-inducing ligand (APRIL) chimeric antigen receptor (CAR) for the treatment of multiple myeloma. more

News

Genmab’s licensing partner, Janssen Biotech, has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for the use of daratumumab (DARZALEX) in front line multiple myeloma. more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline (GSK) for its investigational B-cell mutation agent (BCMA) monoclonal antibody-drug conjugate, for relapsed and refractory multiple myeloma more

News

Genmab has announced that the FDA has approved the use of DARZALEX (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies. more

News

Cogent Skills' recent Labour Force Survey has shown that the UK life sciences sector is severely lacking in young talent. This has prompted EPM to seek out and compile a list of five youngsters who appear to be bucking this trend. more

News